Pharmafile Logo

Genomics extends drug discovery collaboration with Vertex

The new agreement builds on an existing collaboration between the companies
- PMLiVE

Genomics, a science-led TechBio company using large-scale genetic information to develop innovative precision healthcare tools and to accelerate drug discovery and development, has announced a four-year extension of its long-standing drug target discovery and validation collaboration with Vertex Pharmaceuticals. The extension builds on an eight-year collaboration that began in 2018.

The collaboration focuses on using human genetics for the discovery and validation of novel drug targets and biomarker selection for precision medicines, and to advance understanding of the clinical impact of human genetic variation in diseases with significant unmet need. Scientists from Vertex and Genomics will continue to work closely together to incorporate their deep understanding of human genetics into research and development.

Mark Bunnage, Executive Vice President and Chief Scientific Officer at Vertex Pharmaceuticals, said: “A deep understanding of human genetics and the underlying causal biology of diseases is foundational to how we discover and develop transformational therapies at Vertex.”

Professor Sir Peter Donnelly, co-Founder and CEO at Genomics, said: “Our unique platform and our proprietary algorithms allow us to bring the full power of human genetics to understand key biological processes driving disease and to use those insights to find novel targets and powerful biomarkers. Extending this partnership allows us to scale that approach and accelerate the delivery of novel, precision medicines for patients who need them most.”

Professor Chris Molloy, CEO of the BioIndustry Association, UK, added: “This welcome announcement is a powerful vote of confidence in the UK’s world-class life sciences sector. Genomics is a great example of our wealth of innovative, science-led companies that make the UK an attractive place for global biopharma to partner and invest. The multi-year extension of the strategic collaboration with Vertex underlines the global value of the UK’s expertise in human genetics and TechBio, and shows how international investment and national innovation can come together to accelerate the development of new precision medicines for patients around the world.”

The total potential contract value exceeds $220m, for the successful achievement of certain research, development, regulatory and commercial milestones, and tiered royalties on future net sales.

PMGroup
18th November 2026
From: Sales
Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links